Skip to main content

Table 3 Outcome analysis comparing β-lactam versus vancomycin group. Variables were adjusted for predefined confounding variables, including age, sex, age-adjusted Charlson-comorbidity index, Pitt bacteremia score, infectious diseases consultation, infective endocarditis and time to receipt of empiric antibiotics. Duration of bacteremia was further adjusted for surgical source control

From: Comparison of outcomes in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia who are treated with β-lactam vs vancomycin empiric therapy: a retrospective cohort study

Outcomes Crude OR (95 % CI) P-value Adjusted OR (95 % CI) P-value
28-day mortality 0.88 (0.44–1.78) 0.72 1.14 (0.49–2.64) 0.76
90-day mortality 0.75 (0.43–1.32) 0.32 1.01 (0.51–2.02) 0.97
Recurrent infection at 6 months 0.87 (0.31–2.45) 0.79 1.27 (0.39–4.11) 0.69
  Ratio of Mean (95 % CI) P-value Adjusted Ratio of Mean (95 % CI) P-value
Duration of bacteremia 0.92 (0.78–1.07) 0.27 0.94 (0.79–1.11) 0.44
Hospital length-of-stay 0.96 (0.81–1.14) 0.65 0.95 (0.80–1.14) 0.60
  1. Abbreviations: OR odds ratio, CI confidence interval